Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × apatorsen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 2 Squamous Cell Lung Cancer 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuronopathy, Distal Hereditary Motor, Type IIB 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 276 Cisplatin 205 Radiotherapy 182 Paclitaxel 166 Pemetrexed 155 Docetaxel 143 Gemcitabine 132 pembrolizumab 123 Erlotinib Hydrochloride 92 Magnetic Resonance Spectroscopy 89 Etoposide 82 Bevacizumab 74 Specimen Handling 70 Radiosurgery 63 Nivolumab 63 durvalumab 61 Vinorelbine 48 osimertinib 47 Drug Therapy 46 Blood Specimen Collection 44 Gefitinib 40 atezolizumab 37 Surveys and Questionnaires 37 Biopsy 36 Topotecan 35 Irinotecan 35 Radiation 34 Cyclophosphamide 34 Standard of Care 32 Surgical Procedures, Operative 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01829113 2018-06-08

Spruce

SCRI Development Innovations, LLC

Phase 2 Completed

155 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡